Saturday, June 20, 2015 9:35:59 AM
HealthWorld
June 20, 2015
Canadian pharmaceuticual company,Tekmira Pharmaceuticals Corporation has stopped testing their drug formulation on Ebola patients in Sierra Leone, saying it became clear that the drug wasn’t showing any improvement in the patients. The testing was scheduled to end anyway.
“The Phase II clinical trial of TKM-Ebola-Guinea has reached a predefined statistical endpoint and enrollment has been closed,” the company said in a statement.
He added that the drug tested in Sierra Leone was not the same version that had completely protected monkeys from a lethal dose of virus.”It’s not the best product that they have. It’s not the best formulation,” Geisbert said. “This is not what we tested in monkeys.”
Ebola has infected more than 27,000 people in an ongoing epidemic in West Africa, killing more than 11,000 of them. Tragically, this is speculated to rise if the epidemic is not brough under control, since there is no approved treatment for Ebola yet. The disease has a death rate of 50% or more, and all doctors can do is keep patients hydrated, breathing and comfortable.
When the West African epidemic got bad, companies and governments rushed various experimental treatments and vaccines into the filed, from simple blood transfusions from survivors to patients, to more sophisticated plasma transfusions, to drugs such as Tekmira’s, another treatment called ZMapp, and existing antiviral pills.
Fortunately, the epidemic has dropped off but this makes it harder to enroll enough people to test a drug.
The company says it will release full details later.
Geisbert said the company would have been hard-pressed to show that the drug was helping patients in Liberia. “Do you give this product because it’s better than nothing or do you take the safe approach and say sorry, we don’t want to play?” he asked.
“We all want to do the right thing. Everybody wants to save lives.”
Dr. Rick Sacra, an American medical missionary infected in Liberia last year, got Tekmira’s drug and survived. But he also got many other treatments.
The drug uses bits of genetic material called small interfering RNAs, or siRNAs for short.
http://www.esbtrib.com/2015/06/20/17678/canadian-company-halts-ebola-drug-testing-in-sierra-leone/
Recent ABUS News
- Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 04/18/2024 11:30:00 AM
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna • GlobeNewswire Inc. • 04/04/2024 12:30:49 PM
- Arbutus to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 03/08/2024 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 09:48:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:31:15 PM
- Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/29/2024 12:30:00 PM
- Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 02/15/2024 12:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:38:59 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 03:48:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:55:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:55:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:54:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:54:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:31:16 PM
- Arbutus Announces 2024 Corporate Objectives and Provides Financial Update • GlobeNewswire Inc. • 01/08/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:09:10 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 11/21/2023 01:00:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:02:39 PM
- Arbutus to Present at Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/08/2023 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 09:18:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 12:31:16 PM
- Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/07/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 12:16:12 PM
- Arbutus Announces CEO, William Collier, to Retire December 31, 2023 • GlobeNewswire Inc. • 11/07/2023 12:15:00 PM
- Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 10/24/2023 11:30:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM